Education
About Us
Working with TipRanks
Follow Us
SELLAS Life Sciences Group (SLS)
NASDAQ:SLS
RESEARCH TOOLSreports
SLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.77 - $1.84
Previous CloseN/A
Volume1.43M
Average Volume (3M)1.17M
Market Cap
$111.74M
Enterprise Value$63.95M
Total Cash (Recent Filing)$5.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 08, 2025EPS Estimate
-0.11Last Dividend Ex-Date
Apr 27, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding78,581,980
10 Day Avg. Volume745,758
30 Day Avg. Volume1,165,982
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.28
Forecast
1Y Price Target
$4.00Price Target Upside225.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
SELLAS Life Sciences Group News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessSellas announced positive data from a P2a trial for selective CDK9 inhibitor SLS009 combined with the approved BTK inhibitor Brukinsa in relapsed/refractory diffuse large B-cell lymphoma, showing a 67% overall response rate, which is more than double that of zanubrutinib alone.
Pipeline ExpansionThere is potential for SLS009 in ASXL1-mutated solid tumors, which could attract partnership opportunities and expand its application beyond AML.
Regulatory ApprovalThe Independent Data Monitoring Committee recommended continuing the P3 REGAL study for Galipepimut-S in acute myeloid leukemia unmodified, indicating sufficient separation between trial arms to reach its primary endpoint.
Bears Say
Market ConditionsDespite positive trial data, SLS shares were down, possibly due to a slight run-up ahead of the data and some profit-taking, as well as continued pressure in the biotech sector.
Valuation ConcernsA 30% discount rate is applied to the free cash flow, discounted-EPS, and sum-of-the-parts models to derive a 12-month price target of $4.00.
---
Ownership Overview
2.01% Insiders
3.57% Mutual Funds
2.67% Other Institutional Investors
88.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLS FAQ
What was SELLAS Life Sciences Group’s price range in the past 12 months?
SELLAS Life Sciences Group lowest stock price was $0.77 and its highest was $1.84 in the past 12 months.
What is SELLAS Life Sciences Group’s market cap?
SELLAS Life Sciences Group’s market cap is $111.74M.
When is SELLAS Life Sciences Group’s upcoming earnings report date?
SELLAS Life Sciences Group’s upcoming earnings report date is May 08, 2025 which is in 43 days.
How were SELLAS Life Sciences Group’s earnings last quarter?
SELLAS Life Sciences Group released its earnings results on Mar 20, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.107 by $0.047.
Is SELLAS Life Sciences Group overvalued?
According to Wall Street analysts SELLAS Life Sciences Group’s price is currently Undervalued.
Does SELLAS Life Sciences Group pay dividends?
SELLAS Life Sciences Group pays a Notavailable dividend of $7025.8 which represents an annual dividend yield of N/A. See more information on SELLAS Life Sciences Group dividends here
What is SELLAS Life Sciences Group’s EPS estimate?
SELLAS Life Sciences Group’s EPS estimate is -0.11.
How many shares outstanding does SELLAS Life Sciences Group have?
SELLAS Life Sciences Group has 78,581,980 shares outstanding.
What happened to SELLAS Life Sciences Group’s price movement after its last earnings report?
SELLAS Life Sciences Group reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.107. Following the earnings report the stock price went down -0.826%.
Which hedge fund is a major shareholder of SELLAS Life Sciences Group?
Among the largest hedge funds holding SELLAS Life Sciences Group’s share is Highbridge Capital Management LLC. It holds SELLAS Life Sciences Group’s shares valued at 0.
---
SELLAS Life Sciences Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (225.20% Upside)
$4.00 (225.20% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
14.95%
12-Months-Change
Fundamentals
Return on Equity
-4147.88%
Trailing 12-Months
Asset Growth
206.61%
Trailing 12-Months
Company Description
SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
---
SLS Stock 12 Month Forecast
Average Price Target
$4.00
▲(225.20% Upside)
Technical Analysis
Best Analysts Covering SLS
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+2.69%
reiterated a buy rating 5 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +2.69% per trade.
---